Hong Li1, Hyo-Eon Jin, Wooyoung Kim, Yong-Hae Han, Dae-Duk Kim, Suk-Jae Chung, Chang-Koo Shim. 1. National Research Laboratory for Transporters Targeted Drug Design, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, 599 Gwanangno, Gwanak-gu, Seoul 151-742, Republic of Korea.
Abstract
PURPOSE: To investigate the underlying mechanism of low bioavailabilities of the water-soluble camptothecin derivatives, belotecan and topotecan. METHODS: The bioavailability of belotecan and topotecan in rats was determined following oral administration of each drug at a dose of 5 mg/kg body weight. The vectorial transport of each drug was measured in Caco-2 and engineered MDCK II cells. RESULTS: The bioavailability of belotecan (11.4%) and topotecan (32.0%) in rats was increased to 61.5% and 40.8%, respectively, by the preadministration of CsA at a dose of 40 mg/kg. Contrary to the absorptive transport, the secretory transport of these drugs across the Caco-2 cell monolayer was concentration-dependent, saturable, and significantly inhibited by the cis presence of verapamil (a P-gp substrate), MK-571 (an MRP inhibitor), bromosulfophthalein (BSP, an MRP2 inhibitor), fumitremorgin C (FTC, a BCRP inhibitor) and cyclosporine A (CsA, an inhibitor of P-gp and BCRP, and a substrate of P-gp) suggesting the involvement of these transporters, which could be further confirmed in MDCKII/P-gp, MDCKII/MRP2 and MDCKII/BCRP cells. CONCLUSION: The involvement of secretory transporters P-gp, MRP2 and BCRP, particularly for belotecan, as well as a low passive permeability, appears to be responsible for the low bioavailability of belotecan and topotecan.
PURPOSE: To investigate the underlying mechanism of low bioavailabilities of the water-soluble camptothecin derivatives, belotecan and topotecan. METHODS: The bioavailability of belotecan and topotecan in rats was determined following oral administration of each drug at a dose of 5 mg/kg body weight. The vectorial transport of each drug was measured in Caco-2 and engineered MDCK II cells. RESULTS: The bioavailability of belotecan (11.4%) and topotecan (32.0%) in rats was increased to 61.5% and 40.8%, respectively, by the preadministration of CsA at a dose of 40 mg/kg. Contrary to the absorptive transport, the secretory transport of these drugs across the Caco-2 cell monolayer was concentration-dependent, saturable, and significantly inhibited by the cis presence of verapamil (a P-gp substrate), MK-571 (an MRP inhibitor), bromosulfophthalein (BSP, an MRP2 inhibitor), fumitremorgin C (FTC, a BCRP inhibitor) and cyclosporine A (CsA, an inhibitor of P-gp and BCRP, and a substrate of P-gp) suggesting the involvement of these transporters, which could be further confirmed in MDCKII/P-gp, MDCKII/MRP2 and MDCKII/BCRP cells. CONCLUSION: The involvement of secretory transporters P-gp, MRP2 and BCRP, particularly for belotecan, as well as a low passive permeability, appears to be responsible for the low bioavailability of belotecan and topotecan.
Authors: Gracia Merino; Ana I Alvarez; Mivis M Pulido; Antonio J Molina; Alfred H Schinkel; Julio G Prieto Journal: Drug Metab Dispos Date: 2006-01-24 Impact factor: 3.922
Authors: R P Hertzberg; M J Caranfa; K G Holden; D R Jakas; G Gallagher; M R Mattern; S M Mong; J O Bartus; R K Johnson; W D Kingsbury Journal: J Med Chem Date: 1989-03 Impact factor: 7.446
Authors: Anita K Lalloo; Feng R Luo; Ailan Guo; Pankaj V Paranjpe; Sung-Hack Lee; Viral Vyas; Eric Rubin; Patrick J Sinko Journal: BMC Med Date: 2004-05-04 Impact factor: 8.775
Authors: Jun Shen; Angel M Carcaboso; K Elaine Hubbard; Michael Tagen; Henry G Wynn; John C Panetta; Christopher M Waters; Mohamed A Elmeliegy; Clinton F Stewart Journal: Cancer Res Date: 2009-06-30 Impact factor: 12.701